What is Refocus Group?
Refocus Group, Inc. is a Dallas, Texas-based entity dedicated to the research and development of treatments for human vision disorders, with a primary focus on presbyopia. The company's investigational medical device, the VisAbility Micro-Insert System, is currently undergoing clinical trials for binocular presbyopic treatment. Serving both patients and eye care professionals, Refocus Group has been a player in the medical device sector since its founding in 1994.
How much funding has Refocus Group raised?
Refocus Group has raised a total of $15.3M across 2 funding rounds:
Unspecified
$15M
Debt
$350K
Unspecified (2016): $15M with participation from MedCare Investment Funds and WP Global Partners
Debt (2020): $350K led by PPP
Key Investors in Refocus Group
MedCare Investment Funds
MedCare Investment Funds manages approximately $1 billion in assets, primarily focused on the medical and healthcare services industry. They invest across all stages of development, including joint ventures and fully integrated enterprises, offering flexibility due to their private ownership and financing.
WP Global Partners
WP Global Partners backs enterprises essential to U.S. employment and economic growth through a hybrid investment strategy. They focus on small and medium businesses, aiming for risk-adjusted returns and consistent performance by building strong relationships and providing strategic guidance.
What's next for Refocus Group?
The recent major strategic investment in Refocus Group suggests a pivotal moment for the company, likely enabling accelerated clinical trial progression, potential market launch preparations, and further research into its presbyopia treatment technologies. This infusion of capital is expected to bolster the company's efforts to bring its innovative VisAbility Micro-Insert System to market, addressing a significant unmet need in vision care.
See full Refocus Group company page
